How do targeted treatments for IDH1 and IDH2 mutations work in acute myeloid leukemia (AML)?
What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?
The Myeloma 2016 meeting: Integrating science and clinical practice
The differences between biological and chronological age, with their implications on AML treatment
Identifying patients at different risk of relapse in childhood acute lymphoblastic leukemia (ALL)